Densitas Gets Approval for Canada, EU
Weeks after announcing a $250,000 equity investment, Halifax-based Densitas has received regulatory clearance in the European Union and Canada to sell its first product, DM-Density.
When the company revealed its $250,000 funding from Innovacorp in October, it said it would use the money to finance the launch of DM-Density, which enhances breast screening by assessing the density of the breast being examined. Breast density is a key determinant in a patient’s risk of contracting breast cancer, so Densitas helps doctors understand a patient’s risk profile.
“It’s exciting to have